Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 5/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7696744 | 0.88 | RPS6KB2 (0.77) | RPS6KB2ADORA2AADORA1KDM4EPKM | |
| SCHEMBL31393470 | 0.86 | RPS6KB2 (0.74) | RPS6KB2ADORA2AADORA1KDM4ENPC1 | |
| SCHEMBL16027135 | 0.86 | RPS6KB2 (0.74) | RPS6KB2ADORA2AADORA1KDM4ENPC1 | |
| SCHEMBL19066635 | 0.84 | RPS6KB2 (0.71) | RPS6KB2ADORA2AADORA1KDM4ENPC1 | |
| Bromide SCHEMBL19066634 | 0.82 | RPS6KB2 (0.69) | RPS6KB2ADORA2AADORA1KDM4ENPC1 | |
| SCHEMBL31265460 | 0.81 | RPS6KB2 (0.61) | RPS6KB2ADORA2AADORA1KDM4ENPC1 | |
| SCHEMBL578071 | 0.81 | RPS6KB2 (0.61) | RPS6KB2ADORA2AADORA1KDM4ENPC1 | |
| SCHEMBL6237367 | 0.78 | CYP1A2 (0.51) | RPS6KB2ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL6235717 | 0.78 | RPS6KB2 (0.66) | RPS6KB2ADORA2AADORA1KDM4EPKM | |
| SCHEMBL16519335 | 0.78 | RPS6KB2 (0.58) | RPS6KB2ADORA2AKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2805726-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2468285-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2468286-B1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2468287-B1 | Macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2340029-B1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8642538-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8420596-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| CN-101775017-A | macrocyclic hepatitis c serine protease inhibitors | ABBOTT LAB | 2010-07-14 | — | — | CN | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2010030359-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARJMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2005007099-A2 | PKB INHIBITORS AS ANTI-TUMOR AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | RPS6KB2 4418/4885ADORA2A 3736/4885ADORA1 3907/4885 |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | RPS6KB2 893/4885ADORA2A 4281/4885ADORA1 4147/4885 |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | TMPRSS15, PRSS1, SPINT2 | RPS6KB2 4418/4885ADORA2A 3736/4885ADORA1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.